Dr. Kumar on Treatment Options for Patients Who Progress on a BTK Inhibitor in MCL

Now Viewing

EP: 1.Dr. Kumar on Treatment Options for Patients Who Progress on a BTK Inhibitor in MCL

EP: 2.Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL

EP: 3.Dr. Maddocks on the Investigation of Noncovalent BTK Inhibitors in MCL

EP: 4.Dr. Danilov on the Future of BTK Inhibitors in CLL

EP: 5.The Role of Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

EP: 6.Dr. Owen on Choosing Between BTK Inhibitors in CLL

EP: 7.Dr. Torka on the Role of Pirtobrutinib in R/R MCL

EP: 8.BTK Inhibitors in MCL and CLL

EP: 9.Dr. Phillips on BTK Inhibitor Selection in MCL

Anita Kumar, MD, medical oncologist, Regional Care Network Medical Site Director, MSK Basking Ridge, Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with mantle cell lymphoma (MCL) who progress on BTK inhibitors.

Finding suitable treatment options after a patient progresses or is intolerant of a covalent BTK inhibitor remains an unmet need in MCL, Kumar says. Since there are fewer therapeutic options available for those patients, outcomes are unfavorable, Kumar adds. The use of the noncovalent BTK inhibitor pirtobrutinib (LOXO-305) in patients had previously received a covalent BTK inhibitor achieved high response rates, which served as exciting data, Kumar explains.

In addition to its efficacy, pirtobrutinib showed to be a well-tolerated oral therapy with a favorable safety and limited treatment-related adverse effects leading to treatment discontinuation, Kumar continues. Noncovalent BTK inhibitors represent an easily accessible treatment option for patients who progress after traditional covalent BTK inhibitor therapies, Kumar concludes.